Ocular manifestations of systemic malignancies

Current Opinion in Ophthalmology

Volumn 10, Issue 6, 1999, Pages 447-451

  Solomon, Sharon D ^a   Hasenyager Smith, Jennifer ^b   O'Brien, Joan ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; EYE DISEASE; GARDNER SYNDROME; HUMAN; MELANOMA; METASTASIS; NEUROFIBROMATOSIS; OPSOCLONUS; PARANEOPLASTIC SYNDROME; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINOPATHY; UVEA MELANOMA; VISUAL IMPAIRMENT;

DIAGNOSIS, DIFFERENTIAL; EYE DISEASES; EYE NEOPLASMS; HUMANS; NEOPLASMS; PARANEOPLASTIC SYNDROMES;

EID: 0032744918     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199912000-00013     Document Type: Article

References (24)

1. 1 Whitcup SM, Vistica BP, Milam AH, Nussenblatt RB, Gery I: Recoverin-associated retinopathy: a clinically and immunologically distinctive disease. Am J Ophthalmol 1998, 126:230-237. These authors describe a patient with a clinical condition resembling CAR who also demonstrates a cellular immune response against the 23-kD retinal antigen recoverin. The patient has no evidence of active systemic malignancy. The authors propose that this clinical syndrome is distinct from CAR syndrome and have coined the term recoverin-associated retinopathy.
2. 2 Keltner JL, Thirkill CE: Cancer-associated retinopathy vs recoverin-associated retinopathy [editorial]. Am J Ophthalmol 1998, 126:296-302. This interesting editorial provides an excellent review of the history and clinical manifestations of CAR syndrome as well discussing the most recent immunologic observations concerning the role of retinal antigens in the pathogenesis of the disorder.
3. 3 Adamus G, Machnicki M, Elerding H, Sugden B, Blocker YS, Fox DA: Antibodies to recoverin induce apoptosis of photoreceptor and bipolar cells in vivo. J Autoimmun 1998, 11:523-533. The authors of this investigation propose that the photoreceptor cell death in the CAR syndrome occurs through apoptosis and they provide substantial data from an in vivo model to support their hypothesis.
4. 4 McGinnis JF, Austin B, Klisak I, Heinzmann C, Kojis T, Sparkes RS, et al.: Chromosomal assignment of the human gene for the cancer-associated retinopathy protein (recoverin) to chromosome 17p13.1. J Neurosci Res 1995, 40:165-168.
5. 5 Ohguro H, Ogawa K, Nakagawa T: Recoverin and Hsc 70 are found as autoantigens in patients with cancer-associated retinopathy. Invest Ophthalmol Vis Sci 1999, 40:82-89.
6. 6 Adamus G, Amundson D, Seigel GM, Machnicki M: Anti-enolase-α autoantibodies in cancer-associated retinopathy: epitope mapping and cytotoxicity on retinal cells. J Autoimmun 1998, 11:671-677.
7. 7 Boeck K, Hofmann S, Klopfer M, Ian U, Schmidt T, Engst R, et al.: Melanoma-associated paraneoplastic retinopathy: case report and review of the literature. Br J Dermatol 1997, 137:457-460.
8. 8 Guy J, Aptsiauri N: Treatment of paraneoplastic visual loss with intravenous immunoglobulin. Arch Ophthalmol 1999, 117:471-477.
9. 9 Gittinger JW, Smith TW: Cutaneous melanoma-associated paraneoplastic retinopathy: histopathologic observations. Am J Ophthalmol 1999, 127: 612-614. This paper provides an excellent review of MAR syndrome and demonstrates histopathologically that bipolar cells are the major site of paraneoplastic damage.
10. 10 Kiratli H, Thirkill CE, Bilgic S, Eldem B, Kececi A: Paraneoplastic retinopathy associated with metastatic cutaneous melanoma of unknown primary site. Eye 1997, 11:889-892.
11. 11 Kellner U, Bornfeld N, Foerster MH: Severe course of cutaneous melanoma associated paraneoplastic retinopathy. Br J Ophthalmol 1995, 79:746-752.
12. 12 Gass JDM: Neoplastic diseases of the retina and optic disc. In Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment, edn 4. Edited by Craven L. St. Louis: Mosby; 1997:894-896.
13. 13 Singh AD, Milam AH, Shields CL, De Potter P, Shields JA: Melanoma-associated retinopathy. Am J Ophthalmol 1995, 119:369-370.
14. 14 Amin AR, Jakobiec FA, Dreyer EB: Ocular syndromes associated with systemic malignancy. Int Ophthalmol Clin 1997, 37:281-302.
15. 15 Gass JDM, Gieser RG, Wilkinson CP, Beahm DE, Pautler SE: Bilateral diffuse uveal melanocytic proliferation in patients with occult carcinoma. Arch Ophthalmol 1990, 108:527-533.
16. 16 Margo CE, Lowery RL, Kerschmann RL: Lack of p53 protein immunoreactivity in bilateral diffuse uveal melanocytic proliferation. Retina 1997, 17:434-436.
17. 17 Shields CL, Shields JA, Gross NE, Schwartz GP, Lally SE: Survey of 520 eyes with uveal metastases. Ophthalmology 1997, 104:1265-1276.
18. 18 Hartstein ME, Biesman B, Kincaid MC: Cutaneous malignant melanoma metastatic to the eyelid. Ophthalmic Surg Lasers 1998, 29:993-995.
19. 19 Kiratli H, Shields CL, Shields JA, De Potter P: Metastatic tumors to the conjunctiva: report of 10 cases. Br J Ophthalmol 1996, 80:5-8.
20. 20 Shields JA, Shields CL, Kiratli H, De Potter P: Metastatic tumors to the iris in 40 patients. Am J Ophthalmol 1995, 119:422-430.
21. 21 Leys AM, Van Eyck LM, Nuttin BJ, Pauwels PA, Delabie JM, Libert JA: Metastatic carcinoma to the retina: clinicopathologic findings in two cases. Arch Ophthalmol 1990, 108:1448-1452.
22. 22 Gunduz K, Shields JA, Shields CL, Eagle RC: Cutaneous melanoma metastatic to the vitreous. Ophthalmology 1998, 105:600-605.
23. 23 Allaire GS, Corriveau C, Arbour JD: Metastasis to the optic nerve: clinico-pathological correlations. Can J Ophthalmol 1995, 30:306-311.
24. 24 Shields JA, Shields CL, Eagle RC, Gunduz K, Lin B: Diffuse ocular metastases as an initial sign of metastatic lung cancer. Ophthalmic Surg Lasers 1998, 29:598-601.